Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
BIOMERICA INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
- Exchange
- nasdaq
- Notice
- deficiency notice
- Deficiency
- minimum bid price
- Rules
- 5550(a)(2)
Exact text from the filing
May 7, 2024, Biomerica, Inc. (the “Company”) received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price for the Company’s common stock had been below $1.00 per share for the previous 32 consecutive business days and that the Company is no longer in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The Notice has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Capital Market. The Notice indicates the Company will have 180 calenda
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
BIOMERICA INC entered into At Market Issuance Sales Agreement with EF Hutton LLC and R.F. Lafferty & Co., Inc. valued at $5,500,000 (effective 2024-05-10).
- Action
- entry
- Agreement
- atm program
- Counterparty
- EF Hutton LLC and R.F. Lafferty & Co., Inc.
- Value
- $5,500,000
- Effective
- 2024-05-10
Exact text from the filing
On May 10, 2024, Biomerica, Inc. (the “Company”) entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with EF Hutton LLC and R.F. Lafferty & Co., Inc. (each individually, a “Sales Agent” and together, the “Sales Agents”), pursuant to which the Company may offer and sell from time to time up to an aggregate of $5,500,000 of shares of the Company’s common stock
View on SEC.gov